The Geographic Atrophy Market is expected to show positive growth in the forecast period (2022–2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.
DelveInsight’s Geographic Atrophy Market Insights report includes a comprehensive understanding of current treatment practices, Geographic Atrophy emerging drugs, Geographic Atrophy market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
Key takeaways from the Geographic Atrophy Market Report
Know which therapies are expected to grab major Geographic Atrophy Market Share @ Geographic Atrophy Market Research Report
Geographic Atrophy Overview
Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet”. According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.
Currently, there are no approved treatments present for Geographic Atrophy. The Age-Related Eye Disease Study (AREDS) study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene, and zinc could significantly reduce the risk of progressing to advanced AMD, and sometimes low visual aids and counseling is also helpful. Several therapies which reached an advanced stage of development are already failed, however, currently, several therapies are in the pipeline to prevent the progression of GA.
Geographic Atrophy Epidemiology Insights
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Geographic Atrophy Epidemiology Segmentation –
Total Geographic Atrophy Prevalent Cases
Total Geographic Atrophy Diagnosed cases
Treated cases of Geographic Atrophy
Diagnosed cases of Geographic Atrophy by Age Distribution
Total Geographic Atrophy Cases by Visual Impairment
For further information of this report to understand which factors are driving Geographic Atrophy epidemiology trends @ Geographic Atrophy Epidemiological Insights
Geographic Atrophy Market
As per DelveInsight, the Geographic Atrophy Market is expected to grow significantly in the upcoming years owing to the expected launch and readily uptake of emerging therapies along with premium price agents like gene therapies, increasing prevalent patient pool, and a better understanding of pathophysiology, disease severity which might open the door for other companies as well.
Geographic Atrophy Market Dynamics
The Geographic Atrophy (GA) market dynamics is anticipated to change in the coming years owing to the launch of novel drugs and rising healthcare spending across the world.
Geographic Atrophy Pipeline Companies and Therapies
Scope of the Geographic Atrophy Market Report
Table of Content
1. Key Insights
2. Executive Summary of Geographic Atrophy (GA)
3. Competitive Intelligence Analysis for Geographic Atrophy (GA)
4. Geographic Atrophy (GA): Market Overview at a Glance
5. Geographic Atrophy (GA): Disease Background and Overview
6. Patient Journey
7. Geographic Atrophy (GA) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Geographic Atrophy (GA) Unmet Needs
10. Key Endpoints of Geographic Atrophy (GA) Treatment
11. Geographic Atrophy (GA) Marketed Products
12. Geographic Atrophy (GA) Emerging Therapies
13. Geographic Atrophy (GA): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Geographic Atrophy Market Outlook
16. Access and Reimbursement Overview of Geographic Atrophy (GA)
17. KOL Views
18. Geographic Atrophy Market Drivers
19. Geographic Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Discover more about Geographic Atrophy Medications in development @ Geographic Atrophy Clinical Trials
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: YashEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/